Murine double-minute 2 homolog single nucleotide polymorphism 309 and the risk of gynecologic cancer

Human Cell

Volumn 22, Issue 2, 2009, Pages 49-54

  Ueda, Masatsugu ^a,b   Yamamoto, Michiko ^a   Nunobiki, Osamu ^a   Toji, Eisaku ^a   Sato, Naomi ^a   Izuma, Shinji ^a   Okamoto, Yoshiaki ^a   Torii, Kiyo ^a   Noda, Sadamu ^a  

^a Osaka Cancer Prevention and Detection Center   (Japan)

^b Osaka Cancer Prevention and Detection Center   (Japan)

Author keywords

Gynecologic cancer; Murine double minute 2 homolog; P53; Polymorphism; Single nucleotide polymorphism 309

Indexed keywords

PROTEIN MDM2;

ADULT; ALLELE; ARTICLE; BLOOD SAMPLING; CANCER RISK; COMPARATIVE STUDY; CONTROLLED STUDY; ENDOMETRIUM; ENDOMETRIUM CANCER; FEMALE; GENOTYPE; GYNECOLOGIC CANCER; HOMOZYGOTE; HUMAN; HUMAN TISSUE; JAPANESE; MAJOR CLINICAL STUDY; OVARY CANCER; POLYMERASE CHAIN REACTION; POPULATION; POSTMENOPAUSE; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; UTERINE CERVIX; UTERINE CERVIX CANCER;

ASIAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENE FREQUENCY; GENITAL NEOPLASMS, FEMALE; GENOTYPE; HUMANS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS C-MDM2; RISK;

MURINAE;

EID: 64749094671     PISSN: 09147470     EISSN: 17490774     Source Type: Journal    
DOI: 10.1111/j.1749-0774.2009.00068.x     Document Type: Article

References (27)

1. Tsigris C, Chatzitheofylaktou A, Xiromeritis C et al. Genetic association studies in digestive system malignancies. Anticancer Res 2007 27 : 3577 87.
2. Ueda M, Hung YC, Terai Y et al. Glutathione S-transferase GSTM1, GSTT1 and p53 codon 72 polymorphisms in human tumor cells. Hum Cell 2003 16 : 241 51.
3. Ueda M, Toji E, Nunobiki O et al. Germline polymorphism of cancer susceptibility genes in gynecologic cancer. Hum Cell 2008 21 : 95 104.
4. Dulic V, Kaufmann WK, Wilson SJ et al. p53 dependent inhibition of cyclin-dependent kinase activities in human fibroblast during radiation-induced G1 arrest. Cell 1994 76 : 1013 23.
5. Woods DB, Vousden KH. Regulation of p53 function. Exp Cell Res 2001 264 : 56 66.
6. Greenblatt MS, Bennett WP, Hollstein M et al. Mutations in the p53 gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 1994 55 : 4855 78.
7. Chen J, Wu X, Lin J et al. mdm-2 inhibits the G1 arrest and apoptosis functions of the p53 tumor suppressor protein. Mol. Cell. Biol. 1996 16 : 2445 52.
8. Kubbutat MH, Jones SN, Vousden KH. Regulation of p53 stability by Mdm2. Nature 1997 387 : 299 303.
9. Rayburn E, Zhang R, He J et al. MDM2 and human malignancies: expression, clinical pathology, prognostic markers, and implications for chemotherapy. Curr Cancer Drug Targets 2005 5 : 27 41.
10. Bond GL, Hu W, Bond EE et al. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 2004 119 : 591 602.
11. Menin C, Scaini MC, De Salvo GL et al. Association between MDM2-SNP309 and age at colorectal cancer diagnosis according to p53 mutation status. J Natl Cancer Inst 2006 98 : 285 8.
12. Dharel N, Kato N, Muroyama R et al. MDM2 promoter SNP309 is associated with the risk of hepatocellular carcinoma in patients with chronic hepatitis C. Clin Cancer Res 2006 12 : 4867 71.
13. Lum SS, Chua HW, Li H et al. MDM2 SNP309 G allele increases risk but the T allele is associated with earlier onset age of sporadic breast cancers in the Chinese population. Carcinogenesis 2008 29 : 754 61.
14. Meissner Rde V, Barbosa RN, Fernandes JV et al. No association between SNP309 promoter polymorphism in the MDM2 and cervical cancer in a study from northeastern Brazil. Cancer Detect Prev 2007 31 : 371 4.
15. Walsh CS, Miller CW, Karlan BY et al. Association between a functional single nucleotide polymorphism in the MDM2 gene and sporadic endometrial cancer risk. Gynecol Oncol 2007 104 : 660 4.
16. Terry K, McGrath M, Lee IM et al. MDM2 SNP309 is associated with endometrial cancer risk. Cancer Epidemiol. Biomarkers. Prev 2008 17 : 983 6.
17. Campbell IG, Eccles DM, Choong DY. No association of the MDM2 SNP309 polymorphism with risk of breast or ovarian cancer. Cancer Lett 2006 240 : 195 7.
18. Galic V, Willner J, Wollan M et al. Common polymorphisms in TP53 and MDM2 and the relationship to TP53 mutations and clinical outcomes in women with ovarian and peritoneal carcinomas. Genes Chromosomes Cancer 2007 46 : 239 47.
19. Bartel F, Jung J, Böhnke A et al. Both germ line and somatic genetics of the p53 pathway affect ovarian cancer incidence and survival. Clin Cancer Res 2008 14 : 89 96.
20. Yarden RI, Friedman E, Metsuyanim S et al. MDM2 SNP309 accelerates breast and ovarian carcinogenesis in BRCA1 and BRCA2 carriers of Jewish-Ashkenazi descent. Breast Cancer Res Treat 2008 111 : 497 504.
21. Ueda M, Terai Y, Kanda K et al. Germline polymorphism of p53 codon 72 in gynecological cancer. Gynecol Oncol 2006 100 : 173 8.
22. Ueda M, Gemmill RM, West J et al. Mutations of the β- and γ- catenin genes are uncommon in human lung, breast, kidney, cervical and ovarian carcinomas. Br J Cancer 2001 85 : 64 8.
23. Bond GL, Hirshfield KM, Kirchhoff T et al. MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner. Cancer Res 2006 66 : 5104 10.
24. Lax SF. Molecular genetic pathways in various types of endometrial carcinoma: from a phenotypical to a molecular-based classification. Virchows Arch 2004 444 : 213 23.
25. Honda T, Kato H, Imamura T et al. Involvement of p53 gene mutations in human endometrial carcinomas. Int. J. Cancer 1993 53 : 963 7.
26. Kihana T, Hamada K, Inoue Y et al. Mutation and allelic loss of the p53 gene in endometrial carcinoma. Incidence and outcome in 92 surgical patients. Cancer 1995 76 : 72 8.
27. Niwa K, Murase T, Morishita S et al. p53 overexpression and mutation in endometrial carcinoma: inverted relation with estrogen and progesterone receptor status. Cancer Detect Prev 1999 23 : 147 54.